Skip to main content
NIH funding notice RFA-CA-19-013

Immuno-Oncology Translation Network (IOTN): Immuno-engineering to Improve Immunotherapy (i3) Centers (U54 Clinical Trial Not Allowed)

Closed on February 11, 2019.

Posted
October 31, 2018
Close date
February 11, 2019
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

4 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $27,252,540 in first-year total cost, median $6,921,166.

Most frequent study sections

  1. Special Emphasis Panel[ZCA1 RPRB-J (A1)]4

Most frequent institutions

  1. HARVARD UNIVERSITY1
  2. UNIVERSITY OF CALIFORNIA, SAN FRANCISCO1
  3. UNIVERSITY OF PENNSYLVANIA1
  4. UT SOUTHWESTERN MEDICAL CENTER1
Competing awards under RFA-CA-19-013 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2019Biomaterials to Create T Cell Immunity1U54CA244726-01HODI, FRANK SMOONEY, DAVID JHARVARD UNIVERSITY, MA$8,192,428ZCA1
2019UCSF Center for Synthetic Immunology: Tools to Reprogram the Immune System to Combat Cancer1U54CA244438-01LIM, WENDELL AUNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA$7,174,211ZCA1
2019Engineering the Next Generation of T Cells1U54CA244711-01JUNE, CARL H.UNIVERSITY OF PENNSYLVANIA, PA$6,668,121ZCA1
2019Nano-Immuno-Oncology Approaches to Overcome Tumor Immune Evasion1U54CA244719-01GAO, JINMINGUT SOUTHWESTERN MEDICAL CENTER, TX$5,217,780ZCA1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-12-0.1.3. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

RFA-CA-19-013: Immuno-Oncology Translation Network (IOTN): Immuno-engineering to Improve Immunotherapy (i3) Centers (U54 Clinical Trial Not Allowed) | ScienceDex | ConductScience